InvestorsHub Logo
Followers 59
Posts 2267
Boards Moderated 0
Alias Born 02/13/2016

Re: ggwpq post# 106931

Friday, 05/26/2017 8:43:46 AM

Friday, May 26, 2017 8:43:46 AM

Post# of 423548

Given V's safety profile compared with other lipid agents in the market, if Amarin is a "person", it has a serious case of discrimination Vs. the FDA.



Had they continued to approve other drugs based on lipid effects after they lost faith in surrogate outcomes in this space then I would agree with you.


Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News